1.
|
Spillane JB and Henderson MA: Cancer stem
cells: a review. ANZ J Surg. 77:464–468. 2007. View Article : Google Scholar : PubMed/NCBI
|
2.
|
Fillmore CM and Kuperwasser C: Human
breast cancer cell lines contain stem-like cells that self-renew,
give rise to pheno-typically diverse progeny and survive
chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Yang JP, Liu Y, Zhong W, Yu D, Wen LJ and
Jin CS: Chemoresistance of CD133+ cancer stem cells in
laryngeal carcinoma. Chin Med J (Engl). 124:1055–1060.
2011.PubMed/NCBI
|
4.
|
Zhou L, Wei X, Cheng L, Tian J and Jiang
JJ: CD133, one of the markers of cancer stem cells in Hep-2 cell
line. Laryngoscope. 117:455–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Sharma BK, Manglik V, O’Connell M, et al:
Clonal dominance of CD133+ subset population as risk
factor in tumor progression and disease recurrence of human
cutaneous melanoma. Int J Oncol. 41:1570–1576. 2012.
|
6.
|
Yin T, Wei H, Gou S, et al: Cancer
stem-like cells enriched in panc-1 spheres possess increased
migration ability and resistance to gemcitabine. Int J Mol Sci.
12:1595–1604. 2011. View Article : Google Scholar : PubMed/NCBI
|
7.
|
McWhinney SR, Goldberg RM and McLeod HL:
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 8:10–16.
2009. View Article : Google Scholar
|
8.
|
Price KA and Cohen EE: Current treatment
options for metastatic head and neck cancer. Curr Treat Options
Oncol. 13:35–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Ammon HP and Wahl MA: Pharmacology of
Curcuma longa. Planta Med. 57:1–7. 1991.
|
10.
|
Reuter S, Eifes S, Dicato M, Aggarwal BB
and Diederich M: Modulation of anti-apoptotic and survival pathways
by curcumin as a strategy to induce apoptosis in cancer cells.
Biochem Pharmacol. 76:1340–1351. 2008. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Teiten MH, Eifes S, Dicato M and Diederich
M: Curcumin-the paradigm of a multi-target natural compound with
applications in cancer prevention and treatment. Toxins (Basel).
2:128–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Li L, Braiteh FS and Kurzrock R:
Liposome-encapsulated curcumin: in vitro and in vivo effects on
proliferation, apoptosis, signaling, and angiogenesis. Cancer.
104:1322–1331. 2005. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Yamano Y, Uzawa K, Saito K, et al:
Identification of cisplatin-resistance related genes in head and
neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010.
View Article : Google Scholar : PubMed/NCBI
|
14.
|
Visvader JE and Lindeman GJ: Cancer stem
cells: current status and evolving complexities. Cell Stem Cell.
10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Bertolini G, Roz L, Perego P, et al:
Highly tumorigenic lung cancer CD133+ cells display
stem-like features and are spared by cisplatin treatment. Proc Natl
Acad Sci USA. 106:16281–16286. 2009.PubMed/NCBI
|
16.
|
de Jonge-Peeters SD, Kuipers F, de Vries
EG and Vellenga E: ABC transporter expression in hematopoietic stem
cells and the role in AML drug resistance. Crit Rev Oncol Hematol.
62:214–226. 2007.PubMed/NCBI
|
17.
|
Sarkadi B, Ozvegy-Laczka C, Német K and
Váradi A: ABCG2 - a transporter for all seasons. FEBS Lett.
567:116–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Zhou S, Schuetz JD, Bunting KD, et al: The
ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem
cells and is a molecular determinant of the side-population
phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
19.
|
An Y and Ongkeko WM: ABCG2: the key to
chemoresistance in cancer stem cells? Expert Opin Drug Metab
Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Hirschmann-Jax C, Foster AE, Wulf GG,
Goodell MA and Brenner MK: A distinct ‘side population’ of cells in
human tumor cells: implications for tumor biology and therapy. Cell
Cycle. 4:203–205. 2005.
|